title: Time course of the effect of nifedipine therapy and its discontinuation on [Ca2+]i and phagocytosis of polymorphonuclear leukocytes from hemodialysis patients.
abstract: The abnormalities in [Ca2+]i and phagocytosis of polymorphonuclear leukocytes (PMNLs) from hemodialysis (HD) patients are significantly improved by their treatment with nifedipine. However, the rapidity with which this agent induces its beneficial effect and whether these derangements re-emerge after cessation of therapy are not known. We studied 5 HD patients before, during and after treatment with nifedipine. Before treatment with this agent, the basal levels of [Ca2+]i of PMNLs were markedly elevated 73 +/- 3.6 nM (normal: 42 +/- 0.09 nM) and their phagocytic ability markedly reduced (73 +/- 7.4 micrograms oil/10(7) PMNLs/min (normal: 153 +/- 3.8 micrograms oil/10(7) PMNLs/min). After 1 month of therapy, [Ca2+]i fell significantly (p < 0.01) to 53 +/- 1.0 nM with further decrement of a value of 40 +/- 0.9 nM by the end of 3 months of treatment. The levels of [Ca2+]i rose significantly (p < 0.01) to 61 +/- 2.1 nM after 1 month of cessation of therapy and were 69 +/- 2.5 nM by the end of 5 months; these values are not different from those observed before therapy. Phagocytosis improved significantly (p < 0.01) after 1 month of nifedipine therapy (107 +/- 3.9 micrograms oil/10(7) PMNLs/min) with no further improvement during the other 2 months of therapy. Only modest decrement in phagocytosis occurred during the first 3 months after cessation of nifedipine administration; marked and significant impairment (p < 0.01) in phagocytosis (80 +/- 2.6 micrograms oil/10(7) PMNLs/min) became evident at the end of the fifth month. The results show that (1) nifedipine treatment of HD patients rapidly reversed the elevation in [Ca2+]i of their PMNLs but discontinuation of the therapy is followed by rapid re-emergence of the elevation in the [Ca2+]i of the PMNLs; (2) nifedipine therapy causes rapid and significant, but only partial, improvement of phagocytosis, by PMNL of HD patients; almost 5 months is needed before a significant deterioration in phagocytosis becomes evident after stopping nifedipine treatment; (3) the elevation in [Ca2+]i of PMNLs of HD patients plays an important role in the pathogenesis of impaired phagocytosis but is only partially responsible for their derangement, and (4) the beneficial effect of nifedipine therapy on phagocytosis makes this drug a useful therapeutic tool to aid HD patients in their fight against infection.
authors.affiliation: Division of Nephrology, University of Southern California, School of Medicine, Los Angeles 90033, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Alexiewicz
authors.forename: M
authors.initials: M
authors.lastname: Smogorzewski
authors.forename: S K
authors.initials: SK
authors.lastname: Gill
authors.forename: M
authors.initials: M
authors.lastname: Akmal
authors.forename: S G
authors.initials: SG
authors.lastname: Massry
mesh_terms: D000328:Adult; D002118:Calcium / Q000097:blood*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D009543:Nifedipine / Q000627:therapeutic use*; D010587:Phagocytosis / Q000187:drug effects*; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D002121:Calcium Channel Blockers; D009543:Nifedipine; D002118:Calcium